Objective: The growth and development of adipose tissue are thought to be associated with angiogenesis and extracellular matrix remodeling. As the composition of the herbal extract called Ob-X has been shown to have both anti-angiogenic and matrix metalloproteinase (MMP)-inhibiting activities, we hypothesized that growth of adipose tissue can be regulated by Ob-X. Materials and methods: The effects of Ob-X on angiogenesis and extracellular matrix remodeling were measured using in vitro and ex vivo assays. The effects of Ob-X on adipose tissue growth were investigated in nutritionally obese mice. Results: Ob-X inhibited angiogenesis in a dose-dependent manner in the human umbilical vein endothelial cell tube formation assay in vitro and the rat aortic ring assay ex vivo. Ob-X also suppressed MMP activity in vitro. Administration of Ob-X to high fat diet-induced obese mice produced significant reductions in body weight gain and adipose tissue mass compared with control. The mass of both visceral (VSC) and subcutaneous (SC) fat was reduced in Ob-X-treated mice. The size of adipocytes in VSC and SC adipose tissues was also significantly reduced in Ob-X-treated mice. Ob-X treatment decreased the blood vessel density and MMP activity in VSC adipose tissues of nutritionally obese mice. Ob-X reduced mRNA levels of angiogenic factors (VEGF-A and FGF-2) and MMPs (MMP-2 and MMP-9), whereas it increased mRNA levels of angiogenic inhibitors (TSP-1, TIMP-1 and TIMP-2) in SC and VSC adipose tissues of nutritionally obese mice. Conclusion: Ob-X, which has anti-angiogenic and MMP-inhibitory activities, reduces adipose tissue mass in nutritionally induced obese mice, providing evidence that adipose tissue growth and development may be prevented by inhibiting angiogenesis. In addition, these data suggest that regulation of adipose tissue growth by inhibiting angiogenesis may alter the expression of genes involved in angiogenesis and the MMP system.
Introduction
Obesity is the result of an energy imbalance caused by an increased ratio of caloric intake to energy expenditure. In conjunction with obesity, related metabolic disorders such as dyslipidemia, atherosclerosis and type 2 diabetes have become global health problems. Obesity is characterized by increased adipose tissue mass that results from both increased fat cell number (hyperplasia) and increased fat cell size (hypertrophy). 1 Development of obesity is associated with extensive modifications in adipose tissue involving adipogenesis, angiogenesis and remodeling of extracellular matrix (ECM). 2 Similar to neoplastic tissues, angiogenesisFthe formation of new blood vessels from pre-existing vesselsFoccurs in the growing adipose tissue of adults. 2 Most tissues normally do not grow throughout adulthood, and the supporting vasculature is quiescent, 3 whereas adipose tissue can grow and regress throughout life. Adipose tissue is highly vascularized, and each adipocyte is nourished by an extensive capillary network. 2, 4, 5 It is suggested, therefore, that adipose tissue growth is angiogenesis-dependent and may be inhibited by angiogenesis inhibitors. This is supported by reports that treatment with angiogenesis inhibitors resulted in weight reduction and adipose tissue loss, showing that adipose tissue mass is sensitive to angiogenesis inhibitors and can be regulated by its vasculature. [6] [7] [8] Extensive changes in ECM remodeling have also been shown to occur during adipose tissue growth. Two types of proteolytic systems, the plasminogen/plasmin (fibrolytic) and matrix metalloproteinase (MMP) systems, have been implicated in tissue remodeling, via degradation of ECM and basement membrane components, or activation of adipocyte growth factors. 9, 10 The MMP system has important roles in the development of adipose tissue and microvessel maturation by modulating ECM. [10] [11] [12] In most cases, MMPs are expressed at very low levels, but expression is rapidly induced at times of active tissue remodeling associated with adipogenesis. Several lines of evidence suggest that endogenous and exogenous MMPs regulate adipogenesis. [12] [13] [14] During obesity, MMP expression is modulated in adipose tissue, and MMPs (for example, MMP-2 and MMP-9) potentially affect adipocyte differentiation. 12, 15, 16 High expression of MMP-2 was observed in the adipose tissue of mice with nutritionally induced obesity, as well as in genetically obese mice. 17 More clearly, MMP inhibition impairs development of adipose tissue in mice. 18 Thus, the adipocyte-derived MMPs may be new targets for the inhibition of adipose tissue growth. Adipose tissue produces angiogenic factors, such as vascular endothelial growth factor (VEGF)-A and fibroblast growth factor (FGF)-2, contributing to the formation of new blood vessels inside the fat pad. [19] [20] [21] VEGF-A and FGF-2 stimulate proliferation and migration of endothelial cells (ECs) and enhance adipocyte differentiation. [22] [23] [24] Adipose tissue also secretes several MMPs, including MMP-2 and MMP-9. 12 Indeed, it is well established that degradation of ECM represents the first step in the angiogenic process, and that MMP-2 and MMP-9 have been shown to be necessary for this event, 25 indicating the synergistic actions of angiogenesis and the MMP system on the regulation of adipose tissue growth. We screened anti-angiogenic and MMP inhibitory activities of water extracts from medicinal herbs and plants, which have been used for a long period of time, and selected three herbal extracts Melissa officinalis L. (Labiatae; lemon balm), Morus alba L. (Moraceae; white mulberry), and Artemisia capillaris Thunb. (Compositae; injin) to make Ob-X. 26 Accordingly, we thought it plausible that growth and development of adipose tissue can be effectively regulated by Ob-X, with both anti-angiogenic and MMP-2-inhibiting properties. We treated high fat diet-induced obese mice with Ob-X. Body weight gain and adipose tissue mass, as well as adipocyte size, were significantly reduced in Ob-X-treated mice compared with controls. Blood vessel density and MMP activity were also decreased in adipose tissue of treated mice. The expression of angiogenic factors, MMPs and their inhibitors in adipose tissue was markedly modulated by Ob-X. These studies suggest that Ob-X can reduce the adipose tissue mass by targeting adipose tissue.
Materials and methods
Preparation of Ob-X Ob-X was prepared from the food grade of aqueous extracts of the three herbs Melissa officinalis L. ( Cell viability assay HUVEC were cultured and divided into 96-well plates (5000 cells per well), and Ob-X at doses of 10, 25, 50, 100 and 200 mg ml -1 was added into each well except control. After one day, the viability of HUVECs was measured by the XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide disodium salt) test using cell proliferation kit II (Roche, Basel, Switzerland). All manipulations were repeated and performed in triplicate.
Rat aortic ring assay
The effect of Ob-X on angiogenesis was studied by culturing aortic explants in three-dimensional matrix gels, using a slightly modified version of the procedure described by Kruger and Figg. 27 Forty eight-well tissue culture plates were coated with 100 ml of Matrigel and allowed to set for 30 min at 37 1C in an atmosphere of 5% CO 2 . Thoracic aortas were excised from 8-to 10-week-old male Sprague-Dawley rats (SLC, Shizuoka, Japan), and the fibroadipose tissue was removed. The aortas were sectioned into 1-mm long cross sections, rinsed several times with cold endothelial cell basal medium-2 (EBM-2, Lonza), placed on the Matrigel-coated wells, and covered with an additional 50 ml of Matrigel. Matrigel was allowed to gel for 30 min at 37 1C in 5% CO 2 and aortic rings were cultured for 24 h with 200 ml of MMP assay MMP activities were measured on a spectrofluorometer LS50B (Perkin-Elmer, Waltham, MA, USA) using 2,4-dinitrophenyl-Pro-Leu-Gly-Met-Trp-Ser-Arg (Calbiochem, San Diego, CA, USA) as a substrate for MMP-2 and MMP-9. Recombinant human MMP-2 and MMP-9 were purchased from R&D Systems (Minneapolis, MN, USA) and used after activation with 1 mM APMA before the assay. MMP (10 nM) and substrate (1 mM) were mixed in 2 ml of reaction buffer (50 mM Tricine, pH 7.5, 10 mM CaCl 2 , 200 mM NaCl) with or without Ob-X. Fluorescence intensity was measured at room temperature using a 280-nm excitation wavelength and a 360-nm emission wavelength.
Animal study
Eight-week-old male wild-type C57BL/6J mice (n ¼ 8/group) were purchased from SLC and randomly divided into three groups. Mice were fed for 12 weeks with a low fat diet (normal group; 13% kcal fat, CJ, Incheon, Korea), a high fat diet (control group; 45% kcal fat, Research Diets, New Brunswick, NJ, USA), or the same high fat diet supplemented with Ob-X (Ob-X group; 0.2%, w/w). Body weights were measured daily by a person blinded to each treatment group. Food intake was determined by estimating the amount of food consumed by the mice throughout the treatment period. Cages were inspected for food spillage, but only a little spillage was noticed and collected to measure the food intake. After a 12-h fast on the last day of the study, the animals were killed by cervical dislocation. Blood was collected from the retro-orbital sinus into tubes, and serum was separated and stored at À80 1C until analysis. Visceral (VSC) and subcutaneous (SC) fat pads were removed, weighed, snap frozen in liquid nitrogen and stored at À80 1C until use. Portions were prepared for histology. All animal experiments were approved by the Institutional Animal Care and Use Committees of Mokwon University, and followed National Research Council Guidelines.
Determination of serum glucose, insulin, triglyceride and free fatty acid levels Levels of triglycerides and glucose were measured using an automatic blood chemical analyzer (CIBA Corning, Oberlin, OH, USA). Levels of free fatty acids and insulin were measured using SICDIA NEFAZYME (Shinyang Chemical, Seoul, Korea) and an insulin radioimmunoassay kit (Linco, St Charles, MO, USA), respectively.
Histological analysis
For hematoxylin and eosin (H&E) staining, epididymal and inguinal adipose tissues were fixed in 10% phosphatebuffered formalin for 1 day and processed in a routine manner for paraffin sections. Tissue sections (5 mm) were cut and stained with H&E for microscopic examination. To quantify adipocyte number and size, the H&E-stained sections were analyzed using the Image-Pro Plus analysis system.
Blood vessel staining was performed using a blood vessel staining kit (Chemicon, Billerica, MA, USA). Epididymal adipose tissues were fixed in 10% phosphate-buffered formalin for 1 day and processed in a routine manner for paraffin sections. Sections of 3-mm thickness were cut and irradiated in a microwave oven for the epitope retrieval. Sections were incubated with a rabbit anti-von Willebrand Factor antibody as a primary antibody, goat anti-rabbit antibody as a secondary antibody, and streptavidin-alkaline phosphatase solution. A freshly prepared chromogen reagent was added to sections for the visualization of blood vessel.
Zymography MMP activity in the adipose tissue extract was determined by gelatin zymography. Epididymal and inguinal adipose tissues were weighed and extracted with 10 mM sodium phosphate buffer (pH 7.2) containing 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate and 0.2% NaN 3 (250 mg wet weight tissue per 1 ml of buffer) at 4 1C. Protein concentrations in the adipose tissue extracts were quantified using Bicinchonic acid protein assay reagent (Pierce, Rockford, Illinois, USA). Adipose tissue extracts were mixed with zymography sample buffer (63 mM Tris-HCl, 10% Glycerol, 2% SDS, 0.0025% Bromophenol blue, pH 6.8) without heat denaturation. Culture medium of HT1080 cells was used for the molecular weight markers for MMP. Electrophoresis was performed on 10% SDS polyacrylamide gels containing 0.1% gelatin at 125 V. After electrophoresis, the gels were incubated in renaturing buffer of 0.25% Triton X-100 for 30 min at room temperature, and equilibrated in developing buffer (50 mM Tris base, 40 mM HCl, 200 mM NaCl, 5 mM CaCl 2 , 0.2% Brij-35) for 30 min at room temperature. The gels were then incubated in developing buffer overnight at 37 1C. The gels were stained with 0.1% Coomassie Blue R-250 and destained with 10% acetic acid in 40% methanol.
RT-PCR
Total cellular RNA from retroperitoneal and inguinal adipose tissues was prepared using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). After 2 mg total RNA was 
Results

Effects of Ob-X on angiogenesis
The effect of Ob-X on angiogenesis was examined by in vitro HUVEC tube formation assay. Figure 1a shows the capillarylike tubular network structure formed by HUVEC in the control. When Ob-X was added to the culture, the capillarylike tube formation of HUVEC was inhibited in a dosedependent manner compared with control. The percentage of tubule area by Ob-X treatment at the concentrations of 25, 50 and 100 mg ml -1 decreased by 23, 31, and 43%, respectively. Ob-X 25 μg/ml Control Ob-X 50 μg/ml Ob-X 100 μg/ml
Control
Ob-X 50 μg/ml
Ob-X 100 μg/ml
Ob-X 200 μg/ml 
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The cell viability assay showed that 93% of the HUVEC were viable even in the presence of 200 mg ml -1 of Ob-X by the XTT test. Thus the inhibition of HUVEC tube formation by Ob-X at these concentrations was not due to the cell cytotoxicity.
The effect of Ob-X on angiogenesis was further studied using an ex vivo rat aortic ring assay, which has been shown to correlate well with in vivo events of neovascularization. In this assay, the rat aortic endothelium exposed to a threedimensional matrix containing angiogenic factors switches to a microvascular phenotype generating branching networks of microvessels. 28 As shown in Figure 1b , microvessels grew out from the rat aorta in the control when cultured in the medium containing VEGF only. The anti-angiogenic activity was quantified by measuring the cell-sprouting area around the aortas exposed to the various concentrations of Ob-X. The anti-angiogenic effect of Ob-X on the sprouting of microvessels from rat aorta was dose-dependent and microvessel growth was significantly inhibited in the presence of 200 mg ml -1 Ob-X.
Effect of Ob-X on MMP activity
The effect of Ob-X on MMP activity was examined with a spectrofluorometric method using human recombinant MMPs and a quenched fluorescent peptide as a substrate. Ob-X inhibited MMP-2 and MMP-9 activities with IC 50 value of 31.3±1.02 mg ml -1 and 49.1±0.96 mg ml Effects of Ob-X on body weight, adipose tissue mass and adipocyte size in obese mice Because Ob-X showed anti-angiogenic and MMP-inhibitory activities, it was undertaken to determine whether Ob-X reduces adipose tissue mass in nutritionally obese mice. Wild-type C57BL/6J mice were fed with a low fat diet (normal group), a high fat diet (control group) or the same high fat diet supplemented with 0.2% Ob-X (Ob-X group) for 12 weeks. Control mice had 71% higher body weight gain compared with normal mice. Body weight gain for Ob-Xtreated mice was 24% lower than that for control mice (7.29±1.14 g versus 9.60±0.54 g, respectively) ( Table 2) . VSC fat and SC fat weights were decreased by 38 and 45% in treated mice compared with control mice, respectively. Compared with control mice, treated mice had lower VSC fat mass (2.64±0.41 g versus 1.65±0.27 g, respectively) and SC fat mass (1.77 ± 0.25 versus 0.97 ± 0.13 g, respectively). In addition, brown fat was decreased by 13% in Ob-X group compared with control group whereas liver, kidney and heart weights were not changed by Ob-X treatment (data not shown). However, control and treated mice were found to have similar food consumption profiles through the study (Figure 3) .
Analysis of H&E-stained adipose tissue sections from dietinduced obese mice revealed that the size of adipocytes in adipose tissue of Ob-X-treated mice was markedly smaller than that in control mice (Figure 4) . The size of VSC adipocytes in Ob-X-treated mice (2505 ± 308 mm and MMP-9 activities by Ob-X was measured by the spectrofluorometry, and the IC 50 value was determined. *Po0.05 versus vehicle group. ).
Effects of Ob-X on vascularization in VSC adipose tissue of obese mice
To determine whether the decrease of adipose tissue mass by Ob-X is resulted from the inhibition of angiogenesis, we studied the effects of Ob-X on blood vessel density in VSC adipose tissue. Staining of VSC adipose tissue sections with an antibody against von Willebrand Factor, an endothelial cell marker, showed that blood vessel density of Ob-Xtreated mice was lower than that of controls ( Figure 5 ).
Effects of Ob-X on MMP activity in VSC adipose tissue of obese mice MMP activity in adipose tissue extracts was examined using zymography on gelatin-containing gels. Gelatin zymography revealed that the activity of proMMP-2 was significantly reduced in the adipose tissue from Ob-X-treated mice compared with the control group, whereas proMMP-9 levels were not detectable ( Figure 6 ). The proMMP-2 activities in VSC and SC adipose tissues of Ob-X-treated mice were reduced by 33 and 27%, respectively. 
Control
Ob-X Figure 5 Histological analysis of the blood vessels in visceral adipose tissue stained with an antibody against von Willebrand Factor. The blood vessels of epididymal white adipose tissue derived from mice fed with a high fat diet (control group) or a high fat diet supplemented with Ob-X (Ob-X group) for 12 weeks were stained and analyzed (original magnification Â 100).
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mRNA expression of angiogenic factors, MMPs, and their inhibitors in VSC and SC adipose tissues of obese mice treated with Ob-X The expression patterns of genes involved in angiogenesis were investigated in VSC and SC adipose tissue from obese mice treated with Ob-X. The mRNA expression of angiogenic and anti-angiogenic factors was downregulated and upregulated, respectively, in Ob-X-treated mice compared with controls. After Ob-X administration the mRNA levels of angiogenic factors VEGF-A and FGF-2 were reduced by 59 and 48%, respectively, in VSC adipose tissue (Figure 7a) , and by 45 and 14%, respectively, in SC adipose tissue (Figure 7b ). In contrast, the mRNA level of anti-angiogenic molecule thrombospondin-1 (TSP-1) was elevated by 64% in VSC and by 60% in SC fat pads.
Similarly, MMP mRNA expression was inhibited significantly by Ob-X treatment. MMP-2 and MMP-9 were decreased by 42 and 70%, respectively, in VSC adipose tissue, and by 44 and 44%, respectively, in SC adipose tissue. In contrast, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 mRNA levels were increased by 155 and 201%, respectively, in SC adipose tissue and by 25 and 47%, respectively, in VSC adipose tissue from Ob-X-treated mice compared with control mice.
Circulating levels of lipids, glucose and insulin
Circulating levels of free fatty acids and triglycerides were higher by 45 and 47%, respectively, in control group compared with normal group (Table 3) . However, free fatty acid levels decreased by 28%, and triglycerides levels decreased by 31% in Ob-X treated mice compared with those in control mice. Ob-X also caused a decrease in both serum glucose and insulin levels by 33 and 44%, respectively, compared with control animals.
Discussion
Obesity is characterized by excess accumulation of adipose tissue, the growth of which has been reported to require angiogenesis and ECM remodeling. In this study, we prepared Ob-X, a standardized herbal composition with anti-angiogenic and MMP-inhibiting properties, and observed its effects in obese mice. Our results show that Ob-X reduced body weight gain and adipose tissue mass, and markedly modulated the expression of genes involved in angiogenesis and the MMP system in adipose tissue.
Close examination of developing adipose tissue microvasculature revealed that angiogenesis often precedes adipogenesis. 2 The interaction between adipocytes and endothelium is therefore presumed to be involved in the development and maintenance of adipose tissue. Newly formed adipose tissue depends on continued angiogenesis for further growth. 29 It was shown that different angiogenesis inhibitors significantly reduced body weight and adipose tissue mass, 6 strongly indicating a role of angiogenesis in Figure 6 Zymographic analysis of visceral adipose tissue. Extracts from (a) epididymal VSC and (b) inguinal SC adipose tissues obtained from mice fed with a high fat diet (control group) or a high fat diet supplemented with Ob-X (Ob-X group) for 12 weeks were applied to a gelatin-containing gel. Gelatinolytic activity was measured by zymography. All values are expressed as the mean±s.d. *Po0.05 versus control group.
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M-Y Kim et al adipose tissue growth. On the basis of these reports, we primarily examined anti-angiogenic activity of Ob-X, using HUVEC tube formation and rat aorta ring assays. Ob-X inhibited HUVEC tube formation in vitro in a dose-dependent manner without cell cytotoxicity. Ob-X also produced dose-dependent inhibition of VEGF-induced microvessel outgrowth from aortic tissue in the ex vivo rat aortic ring assay. These results show that Ob-X has the ability to inhibit angiogenesis. Ob-X showed the inhibition of two major MMP activities (MMP-2 and MMP-9) in vitro markedly. MMPs have major roles in the ECM remodeling occurring in a variety of physiological and pathological conditions, such as embryonic growth and development, wound healing, atherosclerosis and tumor invasion and metastasis. Moreover, adipocytes are surrounded by a basement membrane that has to be extensively remodeled to allow the hypertrophic development of adipocytes observed in obesity. 30 Recent studies suggest that MMPs have a role in the tissue remodeling events associated with adipogenesis. MMP-2 and MMP-9 can remodel the ECM of murine and human adipogenic cells to facilitate the adipogenic process, 12, 17 and regulate the bio-availability of adipocyte growth factors sequestered as inactive molecules in the matrix, or blocked by interaction with their binding proteins. 31 These results strongly suggest that Ob-X, which has the ability to inhibit MMP activity as well as angiogenesis, can regulate adipose tissue growth. Body weight gain and adipose tissue mass of Ob-X-treated mice were significantly less than those of controls, supporting the hypothesis that Ob-X can reduce adipose tissue growth due to its inhibition of angiogenesis and MMP activity. Ob-X treatment for 12 weeks in high fat diet-fed mice decreased adipose tissue mass by 43%, and this effect was higher than the results showing a 38% reduction after a 12-week administration of galadin, a broad spectrum inhibitor of MMP. 10 Our data are also supported by other results indicating that body weight gain and adipose tissue mass of obese animals were reduced significantly by several kinds of angiogenesis inhibitors. 6, 32 In agreement with earlier studies, 10 Ob-X differentially regulated SC and VSC fat mass in obese mice. SC fat mass was decreased much greater than VSC fat mass. Such differences in regional responses to Ob-X may be due to differences in cellular composition, pattern of MMP expression and secretion of adipokines, which can affect MMP expression. 10, 16, 33, 34 This suggests a role of Ob-X in adipose tissue growth and a differential effect of Ob-X between SC and VSC adipose tissue in animals. However, it may be different in humans, because 1.5 g of Ob-X per day for a 12-week treatment reduced VSC fat area by 9.5% (from 81. ) in a human study of Ob-X with 25 people by computed tomography analysis at 4th lumbar vertebra before and after intervention without changing their life style (unpublished data). In addition to weight reduction, Ob-X inhibited adipocyte hypertrophy in high fat diet-fed obese mice. The size of adipocytes was considerably smaller in Ob-X-treated mice than in controls. Morphometric analysis of SC and VSC adipose tissue histology showed that Ob-X substantially reduced the size of adipocytes in both SC and VSC adipose Inhibition of obesity by angiogenesis inhibitor M-Y Kim et al tissues, eventually resulting in the decreased body weight gain and adipose tissue mass. During Ob-X-induced adipose tissue loss, food intake was not changed. Control and treated mice were found to have similar food consumption profiles. Appetite suppression is a common mechanism of weight loss, which may have many adverse effects. As angiogenesis inhibitors target only growing, or newly formed, immature vessels, anti-angiogenic Ob-X may selectively target adipose tissue and cause weight reduction. The weight loss induced by anti-angiogenic Ob-X came specifically from loss of adipose tissue mass because the weights of any other organs such as liver, kidney and heart were not reduced in Ob-X-treated obese mice.
Under normal physiological conditions, angiogenesis only takes place during embryonic development, wound healing and the female menstrual cycle, and the blood vessels formed under the conditions of normal angiogenesis are mature. But under pathological angiogenesis such as cancer, diabetic retinopathy and abdominal obesity, vascular endothelial cell proliferation occurs very fast in expanding tissue and it is reported that the blood vessels in fast growing tissue such as tumor and adipose tissue are relatively in an immature state compared with those vessels in other organs that are weight-stable. 29 Thus, Ob-X did not show any side effects on organs by targeting only fast growing adipose tissues. Consistent with the inhibitory effects of Ob-X on HUVEC tube formation and microvessel outgrowth from rat aorta, blood vessel density of VSC adipose tissue sections from nutritionally obese mice treated with Ob-X was much lower than in untreated control mice. In contrast to the data presented in this study, the in vivo administration of galardin results in a higher blood vessel density in adipose tissue of mice than in untreated control mice. 10 These inconsistent findings can be explained by normalizing blood vessel density with the number of adipocytes. 14, 35 Zymographic analysis revealed that administration of Ob-X suppressed gelatinolytic activity, especially MMP-2 activity, because proMMP-2 activity was markedly reduced in both VSC and SC adipose tissues, even though MMP-9 activity was not detectable in our tissue samples. It has also been reported that in situ zymography with gelatin-containing gels on cryosections of SC or VSC adipose tissue confirmed a lower MMP activity in tissues of galardin-treated animals. Our present results indicate that the reduction of adipose tissue mass by Ob-X may be due to its anti-angiogenic and MMPinhibiting actions. Diversity of cell populations in the adipose tissue, including preadipocytes, adipocytes, adipose stromal cells, endothelial cells, and inflammatory cells contributes to the production of multiple angiogenic factors and inhibitors that regulate adipose angiogenesis. Angiogenic factors, such as VEGF-A and FGF-2, promote the proliferation and differentiation of endothelial cells within fat, [22] [23] [24] whereas TSP-1 inhibits angiogenesis in vivo and impairs migration and proliferation of cultured microvascular endothelial cells. 36 Adipocytes also produce MMPs and MMP inhibitors that are differentially expressed in adipose tissue during obesity in murine obesity models. 15, 16, 19 Interplay between different factors is presumed to be involved in the development and maintenance of adipose tissue. In our present study, Ob-X administration to high fat diet-induced obese mice decreased the mRNA expression of VEGF-A and FGF-2 responsible for angiogenesis, whereas it increased mRNA level of the anti-angiogenic TSP-1 in both VSC and SC adipose tissues. Similarly, Ob-X decreased MMP-2 and MMP-9 mRNA levels, but increased TIMP-1 and TIMP-2. Our data indicate that Ob-X exerts a specific regulatory effect on genes involved in angiogenesis and the MMP system in adipose tissues. Our observations further show that inhibition of adipose tissue growth by Ob-X may alter the expression of genes responsible for angiogenesis and the MMP system. In addition, we cannot exclude the possibility that Ob-X may also affect adipose tissue growth by changing the expression of other factors.
MMPs have important roles in angiogenesis. MMP inhibitors, both synthetic and endogenous, inhibit angiogenic responses both in vivo and in vitro. [37] [38] [39] [40] Moreover, MMPdeficient mice show delayed or diminished angiogenic responses during development or in response to tumor xenograft. 41 But on the other hand, it was reported that MMP-based proteolysis of the ECM proteins releases cryptic fragments, which are very potent anti-antiogenic substances such as angiostatin 42 and endostatin. 43 High expression of endostatin could be due to the fact that expanding adipose tissue produces MMPs that cleave collagen XVIII into endostatin, showing that inhibiting MMP activity may decrease endogenous angiogenic inhibitors. Several studies showed that MMPs have novel function in adipogenesis, which modulate adipocyte differentiation independent of angiogenesis and therefore MMP inhibitors can block the adipocyte differentiation process. 12, 15, 16, 44 Treatment with MMP inhibitors impairs adipose tissue development in mice fed a high fat diet. 10, 45 Furthermore, the secretion of MMP-2 and MMP-9 increases during adipocyte differentiation in both human adipocytes and mouse preadipocyte cell lines. 12, 15, 16 This suggests that Ob-X can regulate growth and development of adipose tissue by inhibiting MMP activities. Metabolic changes were examined during Ob-X-induced weight loss. Ob-X decreased serum triglyceride and free fatty acid levels. Serum glucose and insulin levels were also decreased by Ob-X in obese mice, which showed hyperinsulinemia and hyperglycemia. These results are consistent with our previous study showing that Ob-X treatment to obese mice increases mRNA expression of enzymes for fatty acid b-oxidation. 26 Thus, it is likely that Ob-X may be used to prevent and treat obesity and obesity-related disorders.
As there is a strong association between visceral adiposity and insulin resistance, Ob-X may have an important role in alleviating hyperlipidemia, insulin resistance and diabetes. [46] [47] [48] Inhibition of obesity by angiogenesis inhibitor M-Y Kim et al
In conclusion, these studies show that Ob-X, which inhibits angiogenesis and MMP activity, regulates adipose tissue growth of nutritionally induced obesity in mice. These events may influence changes in the expression of genes involved in angiogenesis and the MMP system. Thus antiangiogenic Ob-X, by reducing adipose tissue, provides a possible therapeutic approach for the prevention and treatment of human obesity and its related disorders.
